(MedPage Today) — Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults with obesity, both with and without type 2 diabetes, but did not increase the risk of serious adverse events…
Source link : https://www.medpagetoday.com/endocrinology/obesity/117466
Author :
Publish date : 2025-09-15 18:15:00
Copyright for syndicated content belongs to the linked Source.
